Targets › AVBP12A
1 program from 1 company in 2 trials: 2 Phase 2; Infectious disease.
Open in Phaseline: the race on AVBP12A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Washington University School of Medicine | Ivermectin Glutamate-gated chloride channel modulator | AVBP12A | Phase 2 | Onchocercal Subcutaneous Nodule | – |
Onchocercal Subcutaneous Nodule (2)
small molecule (1)
Washington University School of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.